BridgeBio Pharma, Inc. (BBIO)

In the past six months, BridgeBio Pharma's stock has experienced significant activity, delivering a 129.94% change over the past year. BBIO stock tumbled 15% mirroring a broader market decline. Shares declined despite strong analyst support, closing down nearly 4% amid elevated trading volume. Barclays initiated coverage with an "overweight" recommendation. The company reported inducement grants under Nasdaq Listing Rule 5635(c)(4). Shares reached a new 52-week high of $80.69, driven by strong analyst support and optimism following a $632.5 million convertible notes offering. BridgeBio Pharma's CEO sold $2,958,800.00 in stock. The company reported unaudited fourth-quarter 2025 Attruby revenues of $146 million, bringing total 2025 product revenue to $362.4 million, and announced positive interim Phase 3 data for BBP-418 and plans for NDA submissions for BBP-418 and encaleret in H1 2026. BBIO reported its Q3 2025 earnings per share (EPS) of -$0.95, missing analysts' expectations of -$0.82.

Based on a seasonal chart analysis over the past six years, BridgeBio Pharma Inc. has shown a period of seasonal strength. A "Buy Date" of August 17 and a "Sell Date" of November 5 has historically resulted in a geometric average return of 8.83% above the S&P 500 Total Return Index. This seasonal timeframe has outperformed the benchmark in 6 out of 6 periods, suggesting a consistent pattern. This aligns with the broader Healthcare sector's seasonal strength, which typically runs from April 25 to December 4. However, only six years of data are available for BBIO, which may be insufficient to create a fully reliable seasonal profile.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers. The company operates in the Health Technology sector, specifically in the Biotechnology and Pharmaceutical Products industries, leveraging genetic insights to address the root causes of rare diseases and genetically driven cancers. Its pipeline includes Attruby (acoramidis), low-dose infigratinib, encaleret, BBP-418, BBP-831, BBP-631, BBP-711, and NULIBRY (fosdenopterin).

BridgeBio Pharma, Inc. is headquartered in Palo Alto, California, and has expanded its clinical and research activities globally across North America, Europe, and Asia since its inception in 2015. The company collaborates with regulatory agencies and academic centers worldwide and maintains research hubs in major biotech clusters.

BridgeBio Pharma's brand reputation in the past year is largely positive, particularly among analysts, with a consensus rating of "Moderate Buy". Analysts have a consensus price target of $79.05, suggesting a potential upside of 16.16% from its current price. Recent coverage from institutions has reinforced positive outlooks. While there was a recent stock tumble and some profit-taking, these events appear to be market-driven. The increase in short interest by 6.73% in the past month could indicate some decreasing investor sentiment, but the overall news sentiment score for BridgeBio Pharma is 1.50, which is considered higher than the average.

BridgeBio Pharma, Inc. has a diverse ownership structure, with institutional investors holding a significant portion. 703 institutional owners and shareholders held a total of 211,468,714 shares, accounting for approximately 93.93% of the company. Approximately 4.3% of shares are held by individuals, and insiders hold about 20.81% of the company's stock. Kkr Group Partnership LP is the largest individual shareholder, owning 36.90 million shares, representing 19.15% of the company.